Systematic Scrutinisation of Vital Factors for Fabrication and Evaluation of PGS-MCC Based Drug Loaded Pellets by Extrusion Spheronization Technique

Author(s): Hardik Rana, Vaishali Thakkar*, Kalpana Mudgal, Mukesh Gohel, Lalji Baldania, Mansi Dholakia, Tejal Gandhi

Journal Name: Current Drug Therapy

Volume 14 , Issue 2 , 2019

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Objective: The prime objective was to formulate pellet formulation incorporating a newer extrusion- pelletisation aid, Pregelatinised Starch (PGS) and to scrutinise the factors that can affect the quality of the pellets and to overcome the slower disintegration of Microcrystaline Cellulose (MCC).

Methods: Pellets were prepared initially using PGS, MCC, water, ethanol, HPMC K 4 M and Febuxostat was employed as model drug. Optimisation of formulation was done by employing Quality by design (QbD) and Design of experiment (DoE) approach. Ratio of PGS and MCC, ratio of binder and spheronisation speed were selected as independent variables and disintegration time and % cumulative drug release as dependent variables. In vitro in vivo correlation of the optimised batch was carried out using Wagner nelson method. Incompatibility studies have indicated compatibility of drug and excipients.

Results: From the experiments, it was proved that the batch comprising 3:1 ratio of PGS and MCC, 1:1 binder solution and 1500 speed yielded good pellets with decreased disintegration time and improved dissolution rate as compared to pure Febuxostat. IVIVC studies indicated one to one correlation between in vitro and in vivo parameters.

Conclusion: Pellets with good quality, minimum disintegration time and improved dissolution of model drug were successfully prepared with maximum amount of PGS. Optimisation using QbD approach was worth fruitful that affected the quality of pellets.

Keywords: Pellets, pregelatinised starch, MCC, immediate release, convolution, IVIVC.

Sandberg A, Ragnarsson G, Jonsson UE, Sjrgren J. Design of a New Multiple-Unit Controlled-Release Formulation of Metoprolol - Metoprolol CR. Eur J Clin Pharmacol 1988; 33(Suppl S3-7).
Ibrahim MA, El-badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J 2014; 22(2): 149-56.
Yuen KH, Deshmukh AA, Newton JM, Short M, Melchor R. Gastrointestinal transit and absorption of theophylline from a multiparticulate controlled release formulation. Int J Pharm 1993; 97: 61-7.
Dukic-Ott A, Thommes M, Remon JP, Kleinebudde P, Vervaet C. Production of pellets via extrusion - spheronisation without the incorporation of microcrystalline cellulose : A critical review. Eur J Pharm Biopharm 2009; 71: 38-46.
Levina M, Rajabi-siahboomi ALIR. The influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J Pharm Sci 2004; 93(11): 2746-54.
Robinson PC, Horsburgh S. Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 2014; 78(4): 245-51.
Wang J, Kan S, Chen T, Liu J. Application of quality by design (QbD) to formulation and processing of naproxen pellets by extrusion - spheronization. Pharm Dev Technol 2014; 20(2): 246-56.
Pallagi E, Ambrus R, Szabó-révész P, Csóka I. Adaptation of the Quality by Design concept in early pharmaceutical development of an intranasal nanosized formulation. Int J Pharm 2015; 491(1-2): 384-92.
Yan H, Zhang S, He J, Liu J. Application of ethyl cellulose, microcrystalline cellulose and octadecanol for wax based floating solid dispersion pellets. Carbohydr Polym 2016; 148: 143-52.
Ovensten A, Benbow J. Effects of die geometry on the extrusion of clay like material. Trans Br Ceram Soc 1968; 67: 543-67.
Fielden KE, Newton JM. Extrusion and extruders. inEncyclopedia of Pharmaceutical Technology Third. Swarbrick J, Boylan J, editors. . New York and, Basel:: Marcel Dekker 1992; pp. 395-442.
Newton JM. The preparation of spherical granules by extrusion / spheronisation. STP Pharma 1990; 6: 396-8.
Yan X, He H, Meng J, Zhang C, Hong M, Tang X. Preparation of lipid aspirin sustained-release pellets by solvent-free extrusion / spheronization and an investigation of their stability. Drug Dev Ind Pharm 2012; 38(103): 1221-9.
Basit AW, Newton JM, Lacey LF. Formulation of ranitidine pellets by extrusion-spheronization with little or No microcrystalline cellulose. Pharm Dev Technol 1999; 4(4): 499-505.
Sonaglio D, Bataille B, Ortigosa C, Jacob M. Factorial design in the feasibility of producing Microcel MC 101 pellets by extrusion / spheronization. Int J Pharm 1995; 115: 53-60.
Patel N, Thakkar V, Moradiya P, Gandhi T, Gohel M. Optimization of curcumin loaded vaginal in-situ hydrogel by box- behnken statistical design for contraception. J Drug Deliv Sci Technol 2015; 29: 55-68.
Gurram RK, Gandra S, Shastri NR. Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion process using statistical tools. Finance Res Lett 2016; 84: 146-56.
Lutchman D, Dangor CM, Perumal D. Formulation of rate-modulating pellets for the release of ibuprofen : An extrusion-spheronization process. J Microencapsul 2005; 22(6): 643-59.
Lilly E. Development of a multiple unit pellet formulation for a weakly basic drug. Drug Dev Ind Pharm 2007; 33: 341-9.
Goyanes A, Souto C. A comparison of chitosan-silica and sodium starch glycolate as disintegrants for spheronized extruded microcrystalline cellulose pellets. Drug Dev Ind Pharm 2011; 37(7): 825-31.
Gryczová E, Dvořáčková K, Rabišková M. Evaluation of pellet friability Čes slov Farm 2009; 58: 9-13.
Haripriya M. Development of validated UV spectrophotometric methods for the simultaneous estimation of febuxostat and diclofenac potassium in tablet dosage form utilising simultaneous equation and absorbance ratio method. Int J Pharma Bio Sci 2013; 4(3): 134-8.
Bagga P. A simple UV spectrophotometric method for the determination of febuxostat in bulk and pharmaceutical formulations. Int J Pharm Sci Res 2011; 2(10): 2655-9.
Modi N. Development and validation of spectrophotometric method for simultaneous estimation of diclofenac potassium and febuxostat in tablet dosage forms. Pharma Sci Monitor 2012; 3(3): 268-78.
Buskirk GA Van , Shah V, Yacobi A. PQRI Workshop report: application of IVIVC in formulation development. Dissolution Technol. 2014; 51-8.
Cardot J, Beyssac E, Alric M. In Vitro - In Vivo Correlation : Importance of Dissolution in IVIVC Level B. Dissolut Technol 2007; 14(1): 15-9.
Ishak RA, Mortada ND, Zaki NM. El-Shamy Ael-H, Awad GA. Impact of microparticle formulation approaches on drug burst release : a level A IVIVC. J Microencapsul 2014; 31: 674-84.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 26 August, 2019
Page: [168 - 182]
Pages: 15
DOI: 10.2174/1574885514666181123152641
Price: $65

Article Metrics

PDF: 36
PRC: 2